Gambro Report issue

For profit Phase 2
Founded: Lakewood CO United States (1964)
Status: Acquired by Baxalta (2013) → now Takeda (2018)

Organization Overview

First Clinical Trial
2006
NCT00391911
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Gambro Renal Products, Inc. | Gambro UF Solutions, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

acetylcysteine (mucomyst) (1 trial)

Drugs in Other Trials (1)

furosemide (lasix) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Rhabdomyolysis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2